Nuveen LLC Invests $1.81 Million in iTeos Therapeutics, Inc. $ITOS

Nuveen LLC purchased a new position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 303,650 shares of the company’s stock, valued at approximately $1,813,000. Nuveen LLC owned approximately 0.79% of iTeos Therapeutics at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in ITOS. Wells Fargo & Company MN raised its position in shares of iTeos Therapeutics by 16.9% in the 4th quarter. Wells Fargo & Company MN now owns 16,644 shares of the company’s stock worth $128,000 after acquiring an additional 2,402 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of iTeos Therapeutics in the 4th quarter worth $1,159,000. Barclays PLC raised its position in shares of iTeos Therapeutics by 17.4% in the 4th quarter. Barclays PLC now owns 132,894 shares of the company’s stock worth $1,022,000 after acquiring an additional 19,683 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of iTeos Therapeutics by 15.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,210,080 shares of the company’s stock worth $9,293,000 after acquiring an additional 163,880 shares in the last quarter. Finally, Hsbc Holdings PLC raised its position in shares of iTeos Therapeutics by 43.1% in the 4th quarter. Hsbc Holdings PLC now owns 47,406 shares of the company’s stock worth $355,000 after acquiring an additional 14,288 shares in the last quarter. 97.16% of the stock is owned by institutional investors.

iTeos Therapeutics Stock Performance

Shares of ITOS stock opened at $10.15 on Friday. The stock’s 50-day simple moving average is $10.14 and its 200-day simple moving average is $8.44. The firm has a market capitalization of $448.73 million, a PE ratio of -2.17 and a beta of 1.49. iTeos Therapeutics, Inc. has a fifty-two week low of $4.80 and a fifty-two week high of $17.63.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($1.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.39). Sell-side analysts forecast that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ITOS. Piper Sandler lowered iTeos Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 21st. Wedbush reaffirmed an “outperform” rating and set a $10.50 target price (down from $12.00) on shares of iTeos Therapeutics in a research report on Monday, July 21st. Leerink Partnrs lowered iTeos Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 14th. Leerink Partners reaffirmed a “market perform” rating and set a $9.00 target price (down from $47.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Finally, HC Wainwright lowered iTeos Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, May 14th. One equities research analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, iTeos Therapeutics has an average rating of “Hold” and a consensus price target of $15.50.

Insider Transactions at iTeos Therapeutics

In other news, CEO Michel Detheux sold 43,883 shares of the stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $10.02, for a total value of $439,707.66. Following the transaction, the chief executive officer directly owned 153,903 shares of the company’s stock, valued at approximately $1,542,108.06. This represents a 22.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David Hallal sold 38,228 shares of the stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $10.24, for a total value of $391,454.72. The disclosure for this sale can be found here. Insiders sold 277,185 shares of company stock worth $2,805,412 over the last three months. Corporate insiders own 14.20% of the company’s stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.